Interestingly, majority of the small molecule inhibitors of the PI3K signaling module have oral bioavailability (Table 2) which is better suited for the management of chronic diseases like MPN and ensuring patient compliance. The gene discussed is PIK3CA; the disease is myeloproliferative neoplasm.